Regina Tan-Camacho, MD
Internal Medicine · Chesapeake, VANPI 1154366748
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 341 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 341 payments — averaging $15.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$760
- Abbott$518
- AstraZeneca$440
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$413
- Boehringer Ingelheim$399
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,309100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 79 | $1,128 |
| Novo Nordisk | 48 | $760 |
| Abbott | 25 | $518 |
| AstraZeneca | 29 | $440 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 29 | $413 |
| Boehringer Ingelheim | 28 | $399 |
| GSK | 10 | $155 |
| Amgen | 9 | $145 |
| Novartis | 9 | $129 |
| Sanofi-aventis U.S. LLC | 9 | $126 |
| Astellas Pharma US Inc | 6 | $109 |
| Merck | 7 | $108 |
| Axsome Therapeutics, Inc. | 4 | $98 |
| Jazz Pharmaceuticals Inc. | 6 | $86 |
| Lilly USA, LLC | 5 | $75 |
| Amarin Pharma, Inc. | 4 | $67 |
| Pfizer | 4 | $63 |
| E.r. Squibb & Sons, L.L.C. | 3 | $53 |
| Bayer | 2 | $42 |
| Teva Pharmaceuticals USA, Inc. | 3 | $40 |
| Eisai Inc. | 3 | $39 |
| Inspire Medical Systems, Inc. | 1 | $34 |
| Johnson & Johnson | 2 | $30 |
| Inari Medical, Inc. | 1 | $30 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Mylan Specialty L.p. | 2 | $26 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| Ironwood Pharmaceuticals, Inc | 2 | $24 |
| Hikma Pharmaceuticals USA | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Ironshore Pharmaceuticals Inc. | 1 | $19 |
| Almatica Pharma LLC | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
How this compares
$5,330 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 55 | $72,898 |
| EliquisApixaban | 28 | $45,776 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 35 | $35,500 |
| JardianceEmpagliflozin | 26 | $30,469 |
| OzempicSemaglutide | 20 | $28,309 |
| RybelsusSemaglutide | 12 | $26,043 |
| XareltoRivaroxaban | 17 | $22,390 |
| LinzessLinaclotide | 13 | $19,626 |
| MyrbetriqMirabegron | 21 | $18,845 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $14,743 |
| MounjaroTirzepatide | 13 | $11,911 |
| Dexlansoprazole DrDexlansoprazole | 20 | $8,652 |
| TradjentaLinagliptin | 11 | $8,614 |
| Repatha SureclickEvolocumab | 12 | $8,295 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $7,867 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet Xr | $108 | $108,39890 claims |
| Novo NordiskOzempic, Rybelsus | $760 | $54,35232 claims |
| PfizerEliquis | $63 | $45,77628 claims |
| Boehringer IngelheimJardiance, Tradjenta | $399 | $39,08237 claims |
| Johnson & JohnsonXarelto | $30 | $22,39017 claims |
| AbbVieLinzess, Synthroid | $1,128 | $21,01450 claims |
| Astellas Pharma US IncMyrbetriq | $109 | $18,84521 claims |
| GSKBreo Ellipta | $155 | $14,74323 claims |
| Lilly USA, LLCMounjaro | $75 | $11,91113 claims |
| AstraZenecaBreztri Aerosphere | $440 | $7,86712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Chesapeake
- Luis CarpioChesapeake$13K
- Vernis BeverlyChesapeake$13K
- Kumar AbhishekMechanicsville$1M
- Amit MahajanFalls Church$1M
- Kevin DonohueFalls Church$655K
- Denise BrunerArlington$227K
- Anjali KaloreMidlothian$215K
- Scott GerrishVienna$207K
- Lawrence SchwartzRichmond$205K
- Wally SmithRichmond$177K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.